In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Sponsor
Novo Nordisk A/S
Study ID
NCT03479762
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.

Key Dates

Start date
Apr 20, 2018
Status verified
Nov 2022
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022

Study Design

Enrollment
105 participants (actual)

Arms

  • Arm: Liraglutide
    Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)

Primary Outcome Measure

Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only) [ Time Frame: Less than 6 months before the date of the first prescription ]

Related Studies